Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 52, Issue 4, Pages 766-777Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2008.04.011
Keywords
chronic kidney disease; diabetes mellitus; therapy; outcomes
Categories
Funding
- National Institute of Diabetes, Digestive and Kidney Disease of the National Institutes of Health [R01 DK078106, R01 DK063017]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078106, R01DK063017] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Diabetes mellitus (DM) is a leading cause of chronic kidney disease (CKD) and a major source of morbidity and mortality in patients with established CKD. Loss of kidney function and dialytic therapies conspire to change glycemic regulation in ways that can both worsen and improve blood glucose control. Despite the unique nature of DM in patients with CKD, there currently are no specific guidelines to direct glycemic therapy in these patients. There is benefit of glycemic therapy in preventing such complications as diabetic kidney disease and mortality in patients with no kidney disease, but such benefits are largely unproven in patients with advanced CKD. By reviewing the relevant literature, we argue that glycemic control can still be beneficial in preventing complications, even in dialysis-dependent patients, but there is need for a much better understanding of the CKD-related characteristics of DM. More research is needed to determine whether uremia-related improvement in glycemic control can have a beneficial impact. Finally, we are at an important crossroads in the development of several novel therapeutic agents against diabetic kidney disease. We provide an overview of such agents and their stage of development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available